Le Lézard
Classified in: Health, Business
Subjects: NPT, JVN, TRI

Green Park Collaborative and Allergy & Asthma Network Launch coreASTHMA to Develop Consensus on Critical Outcomes in Moderate to Severe Asthma Clinical Research


BALTIMORE, Oct. 15, 2019 /PRNewswire/ -- The Green Park Collaborative (GPC), a major initiative of the Center for Medical Technology Policy (CMTP), is partnering with Allergy & Asthma Network (AAN), to develop a core set of outcomes to be used in pivotal and late phase clinical trials of therapies for moderate to severe asthma. This initiative, coreASTHMA, will engage patients, clinicians, regulators, payers, health technology assessors, product developers, and other key stakeholders in a structured consensus process to develop the core outcome set.

Asthma is a disease of chronic airway inflammation, with symptoms such as coughing, wheezing and shortness of breath impacting patients' daily functioning and quality of life. Despite multiple treatment options for management of asthma, many patients with severe or poorly controlled asthma fail to improve with existing treatments. With recent innovations in immunotherapy, new biologic drugs give hope for long-term control of asthma, particularly in patients who have had limited success with traditional therapies. However, these new drugs come with high price tags and more questions.

"With more biologic therapies for asthma in the drug development pipeline, the timing is ideal to consider how best to evaluate these new treatments for better-informed patient choices and policy assessments," says Donna Messner, President and CEO of CMTP.

"At this critical juncture, we want to ensure the patient voice translates to asthma research and policy decisions," said Tonya Winders, CEO of AAN. "This project will help facilitate a more transparent and patient-centered definition of value in asthma care."

About the Green Park Collaborative (GPC)
GPC is a major initiative of CMTP, an independent 501(c)(3) non-profit organization dedicated to improving the quality, relevance, and efficiency of clinical research. GPC is a multi-stakeholder forum for developing condition- and technology-specific study design recommendations to guide the creation of evidence needed to inform both clinical and payment decisions.

About Allergy & Asthma Network 
AAN is the leading nonprofit patient education and advocacy organization for people with asthma, allergies, and related conditions. AAN's patient-centered network unites individuals, families, healthcare professionals, industry, and government decision makers to improve health and quality of life for Americans with asthma and allergies. We specialize in making accurate medical information relevant and understandable to all while promoting evidence-based standards of care.

 

SOURCE Green Park Collaborative


These press releases may also interest you

at 03:10
AgraFlora Organics International Inc.  ("AgraFlora" or the "Company") , a growth oriented and diversified international cannabis company, is pleased to announce that Farmako GmbH ("Farmako"), through its wholly owned subsidiary Farmako Limited has...

at 03:00
Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on central nervous system (CNS) disorders, today announces the expansion of its operations in Central Europe with the launch of Neuraxpharm Austria, and the...

at 03:00
The 34th annual iaedptm (International Association of Eating Disorders Professionals) Symposium is just weeks away, and this year's event continues the Symposium's reputation for presenting the latest in new treatments and research concerning eating...

at 03:00
Asymmetrex LLC is part of a new public-private Manufacturing USA initiative, the Advanced Regenerative Manufacturing Institute (ARMI). Headquartered in Manchester, New Hampshire, ARMI is the 12th Manufacturing USA Institute. ARMI brings together a...

at 03:00
Evotec SE and Indivumed GmbH ("Indivumed") today announced that the companies have entered into a new research collaboration to discover and develop first-in-class therapeutics for the treatment of non-small cell lung cancer ("NSCLC"). The final...

at 02:05
POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced the appointment of...



News published on 15 october 2019 at 10:13 and distributed by: